<p>Bicycle Therapeutics plc（纳斯达克代码：BCYC - 获取免费报告）在四月份遭遇了空头头寸的大幅下降。截至四月十五日，空头头寸总计为 3,130,000 股，较三月三十一日的 4,300,000 股下降了 27.2%。该公司的约 5.0% 的股份被做空。根据平均每日交易量 349,300 股，目前的覆盖天数比率为 9.0 天。</p>
<p>获取 <strong>Bicycle Therapeutics</strong> 警报：</p>
<h2>分析师评级上调与下调</h2>
<p>几位分析师最近对 BCYC 股票发布了报告。Stephens 在 1 月 22 日的研究报告中重申了 “持平” 的评级，并对 Bicycle Therapeutics 的股票设定了 15.00 美元的目标价。Needham &amp; Company LLC 在 4 月 9 日的研究报告中重申了 “买入” 评级，并将 Bicycle Therapeutics 的目标价设定为 30.00 美元。最后，HC Wainwright 在 2 月 26 日的研究报告中重申了 “买入” 评级，并对 Bicycle Therapeutics 的股票设定了 33.00 美元的目标价。两位研究分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 29.14 美元。</p>
<p><strong>获取我们关于 BCYC 的最新研究报告</strong></p>
<h2>Bicycle Therapeutics 股票表现</h2>
<p>纳斯达克 BCYC 的股票在周四开盘价为 8.56 美元。该公司的市值为 5.9237 亿美元，市盈率为-2.60，贝塔值为 1.40。Bicycle Therapeutics 的 52 周低点为 6.10 美元，52 周高点为 28.67 美元。该公司的 50 日移动平均价格为 8.79 美元，200 日移动平均价格为 14.72 美元。</p>
<p>Bicycle Therapeutics（纳斯达克代码：BCYC - 获取免费报告）最近于 2 月 25 日发布了季度财报。该公司报告每股收益（EPS）为（0.75 美元），超出分析师的共识预期（0.85 美元）0.10 美元。该公司本季度的收入为 370 万美元，而共识预期为 547 万美元。Bicycle Therapeutics 的净利润率为-450.64%，股本回报率为-27.35%。该公司本季度的收入同比下降了 30.2%。在去年同期，该公司每股收益为（1.16 美元）。分析师预测 Bicycle Therapeutics 在当前年度的每股收益将为-3.06 美元。</p>
<h2>机构资金流入与流出</h2>
<p>机构投资者最近调整了对该股票的持有。巴克莱银行在第四季度将其在 Bicycle Therapeutics 的持股比例提高了 878.3%。巴克莱银行目前持有该公司 2,612 股股票，价值 37,000 美元，此前在此期间增持了 2,345 股。Avior Wealth Management LLC 在第四季度新购入了 Bicycle Therapeutics 的股份，价值 57,000 美元。GAMMA Investing LLC 在第一季度将其在 Bicycle Therapeutics 的持股比例提高了 879.5%。GAMMA Investing LLC 目前持有该公司 8,982 股股票，价值 76,000 美元，此前在上个季度增持了 8,065 股。Exchange Traded Concepts LLC 在第一季度将其在 Bicycle Therapeutics 的持股比例提高了 90.3%。Exchange Traded Concepts LLC 目前持有该公司 12,764 股股票，价值 108,000 美元，此前在上个季度增持了 6,057 股。最后，Cerity Partners LLC 在第一季度新购入了 Bicycle Therapeutics 的股份，价值 113,000 美元。机构投资者和对冲基金持有该公司 86.15% 的股票。</p>
<h2>Bicycle Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 期临床试验的自行车毒素结合物（BTC），用于治疗高 nectin-4 表达的肿瘤；BT5528，一种正在进行 I/II 期临床试验的 BTC，用于治疗 Ephrin A 型受体 2 表达的肿瘤；BT7480，一种正在进行 I/II 期的自行车 TICA 分子，针对 Nectin-4 并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的自行车 TICA 分子，目前处于临床前试验阶段。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Bicycle Therapeutics 更好</li>
<li>你应该投资于便士股票吗？</li>
<li>D-Wave 与 Davidson 的项目为何会改变量子计算游戏</li>
<li>关于 Markup 计算器</li>
<li>Hims &amp; Hers 股票因与诺和诺德的合作而飙升</li>
<li>10 美元以下的最佳股票</li>
<li>亚马逊的收益将决定股票的反弹成败</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bicycle Therapeutics 吗？</h2>
<p>在你考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Bicycle Therapeutics 并不在名单上。</p>
<p>虽然 Bicycle Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

BCYC

<p>Bicycle Therapeutics plc（纳斯达克代码：BCYC）在空头头寸方面经历了显著下降，截至 4 月 15 日，下降了 27.2%，降至 3,130,000 股。目前，该公司的股票中有 5.0% 被做空，基于每日平均成交量 349,300 股，覆盖天数比率为 9.0 天。分析师的评级意见不一，普遍评级为 “适度买入”，平均目标价为 29.14 美元。该公司报告的季度每股收益为（$0.75），超出预期，但收入同比下降了 30.2%。机构投资者持有 86.15% 的股份</p>

<p>Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 3,130,000 shares, a decline of 27.2% from the March 31st total of 4,300,000 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average daily volume of 349,300 shares, the days-to-cover ratio is currently 9.0 days.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc（纳斯达克代码：BCYC - 获取免费报告）在四月份遭遇了空头头寸的大幅下降。截至四月十五日，空头头寸总计为 3,130,000 股，较三月三十一日的 4,300,000 股下降了 27.2%。该公司的约 5.0% 的股份被做空。根据平均每日交易量 349,300 股，目前的覆盖天数比率为 9.0 天。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bicycle Therapeutics</strong> 警报：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several analysts recently issued reports on BCYC shares. Stephens restated an &#34;equal weight&#34; rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $29.14.</p>
<div class="lb-trans"><p>几位分析师最近对 BCYC 股票发布了报告。Stephens 在 1 月 22 日的研究报告中重申了 “持平” 的评级，并对 Bicycle Therapeutics 的股票设定了 15.00 美元的目标价。Needham &amp; Company LLC 在 4 月 9 日的研究报告中重申了 “买入” 评级，并将 Bicycle Therapeutics 的目标价设定为 30.00 美元。最后，HC Wainwright 在 2 月 26 日的研究报告中重申了 “买入” 评级，并对 Bicycle Therapeutics 的股票设定了 33.00 美元的目标价。两位研究分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 29.14 美元。</p>
</div><p><strong>Get Our Latest Research Report on BCYC</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 BCYC 的最新研究报告</strong></p>
</div><h2>Bicycle Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ BCYC opened at $8.56 on Thursday. The company has a market capitalization of $592.37 million, a P/E ratio of -2.60 and a beta of 1.40. Bicycle Therapeutics has a 52-week low of $6.10 and a 52-week high of $28.67. The company's 50 day moving average price is $8.79 and its 200-day moving average price is $14.72.</p>
<div class="lb-trans"><p>纳斯达克 BCYC 的股票在周四开盘价为 8.56 美元。该公司的市值为 5.9237 亿美元，市盈率为-2.60，贝塔值为 1.40。Bicycle Therapeutics 的 52 周低点为 6.10 美元，52 周高点为 28.67 美元。该公司的 50 日移动平均价格为 8.79 美元，200 日移动平均价格为 14.72 美元。</p>
</div><p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.16) EPS. Analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current year.</p>
<div class="lb-trans"><p>Bicycle Therapeutics（纳斯达克代码：BCYC - 获取免费报告）最近于 2 月 25 日发布了季度财报。该公司报告每股收益（EPS）为（0.75 美元），超出分析师的共识预期（0.85 美元）0.10 美元。该公司本季度的收入为 370 万美元，而共识预期为 547 万美元。Bicycle Therapeutics 的净利润率为-450.64%，股本回报率为-27.35%。该公司本季度的收入同比下降了 30.2%。在去年同期，该公司每股收益为（1.16 美元）。分析师预测 Bicycle Therapeutics 在当前年度的每股收益将为-3.06 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Barclays PLC lifted its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after acquiring an additional 2,345 shares during the period. Avior Wealth Management LLC acquired a new position in Bicycle Therapeutics during the fourth quarter worth $57,000. GAMMA Investing LLC raised its holdings in Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock worth $76,000 after buying an additional 8,065 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Bicycle Therapeutics by 90.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after acquiring an additional 6,057 shares in the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Bicycle Therapeutics in the 1st quarter worth $113,000. Institutional investors and hedge funds own 86.15% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有。巴克莱银行在第四季度将其在 Bicycle Therapeutics 的持股比例提高了 878.3%。巴克莱银行目前持有该公司 2,612 股股票，价值 37,000 美元，此前在此期间增持了 2,345 股。Avior Wealth Management LLC 在第四季度新购入了 Bicycle Therapeutics 的股份，价值 57,000 美元。GAMMA Investing LLC 在第一季度将其在 Bicycle Therapeutics 的持股比例提高了 879.5%。GAMMA Investing LLC 目前持有该公司 8,982 股股票，价值 76,000 美元，此前在上个季度增持了 8,065 股。Exchange Traded Concepts LLC 在第一季度将其在 Bicycle Therapeutics 的持股比例提高了 90.3%。Exchange Traded Concepts LLC 目前持有该公司 12,764 股股票，价值 108,000 美元，此前在上个季度增持了 6,057 股。最后，Cerity Partners LLC 在第一季度新购入了 Bicycle Therapeutics 的股份，价值 113,000 美元。机构投资者和对冲基金持有该公司 86.15% 的股票。</p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 期临床试验的自行车毒素结合物（BTC），用于治疗高 nectin-4 表达的肿瘤；BT5528，一种正在进行 I/II 期临床试验的 BTC，用于治疗 Ephrin A 型受体 2 表达的肿瘤；BT7480，一种正在进行 I/II 期的自行车 TICA 分子，针对 Nectin-4 并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的自行车 TICA 分子，目前处于临床前试验阶段。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>Should You Invest in Penny Stocks?</li>
<li>Why D-Wave's Project With Davidson Is a Game-Changer For Quantum</li>
<li>About the Markup Calculator</li>
<li>Hims &amp; Hers Stock Soars on Novo Nordisk Collaboration</li>
<li>Best Stocks Under $10.00</li>
<li>Amazon's Earnings Will Make or Break the Stock's Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Bicycle Therapeutics 更好</li>
<li>你应该投资于便士股票吗？</li>
<li>D-Wave 与 Davidson 的项目为何会改变量子计算游戏</li>
<li>关于 Markup 计算器</li>
<li>Hims &amp; Hers 股票因与诺和诺德的合作而飙升</li>
<li>10 美元以下的最佳股票</li>
<li>亚马逊的收益将决定股票的反弹成败</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bicycle Therapeutics 吗？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Bicycle Therapeutics 并不在名单上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bicycle Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Bicycle Therapeutics plc（NASDAQ:BCYC）的空头头寸显著下降